No insider purchase over the last 90 days. The latest was filed 07 Nov 2023.
Oriola Oyj, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to Nasdaq Helsinki. 20 insiders have disclosed 20 filings since 18 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
There has been no open-market purchase by an insider of Oriola Oyj for at least a year. Between a trade and the moment it shows up on Nasdaq Helsinki, the median delay is 1 day. The regulation allows three business days to notify a trade (MAR article 19).
With 20 filings in twelve months, the company is more active than the median of 15 filings across the 126 companies we follow on the same exchange. Since 2023, the database holds 7 purchases and no sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Nasdaq Helsinki. They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 82 declarations
Oriola Oyj is a Finnish company specializing in the distribution of pharmaceutical and healthcare products. It primarily operates in the Nordic market and focuses on improving access to healthcare.
Purchases our model currently ranks for the recommendations list.
All recommendations